Marketing Strategy

Brief overview of Marketing Strategy

BioRegenx and its wholly owned subsidiaries use an omni-channel approach that includes both business-to-business (B2B) and business-to-consumer (B2C) marketing strategies.

MVHS Marketing Strategy

There are three primary markets for GlycoCheck™ and Endocalyx™:

 

  • University Hospitals and Researchers. GlycoCheck™ is currently used in over 120 academic research hospitals worldwide. These professionals provide cutting-edge research, validation, and credibility in multiple clinical studies across a wide range of diseases that support the science. Over 70 peer-reviewed clinical studies using GlycoCheck™ have been published. These studies represent millions of dollars in ongoing research.
  • Medical Professionals. GlycoCheck™ measurement testing is only available from trained and certified medical professionals. This includes medical doctors and naturopathic physicians and wellness-based chiropractors. Marketing initiatives will drive patients to their practices and support them with a system for recurring revenue from testing and supplement sales. There are about 950,000 active doctors in the U.S. Seventy-six percent of medical doctors, naturopathic physicians, chiropractors, and nutritionists sell supplements from their offices.

The medical devices market 2020 size reached nearly $456.9 billion in 2019, having increased at a compound annual growth rate (CAGR) of 4.4% since 2015. The market is expected to decline from $456.9 billion in 2019 to $442.5 billion in 2020 at a rate of -3.2%. The decline is mainly due to lockdowns imposed by the governments across the world that hindered the supply chain in the medical devices manufacturing industry. However, there is an exceptional increase in the manufacturing of the ventilators that are used to treat COVID-19 patients. The medical devices market is expected to recover and grow at a CAGR of 6.1% from 2021 and reach $603.5 billion in 2023. This is because as mentioned, beyond 2020, an increase in the incidences of infectious and chronic diseases will drive the market growth. Analysis of the medical device market by country shows that North America accounts for about 39%, the largest share in the global market. Source: October 27, 2020, The Business Research Company.

 

  • Direct-to-Consumer. Marketing initiatives will include paid and online media, video, social media, pay-per-click, affiliate partnerships, print, direct mail and broadcasting. The dietary supplements market is expected to grow at a compound annual growth rate of 8.6% from 2021 to 2028 to reach USD $272.44 billion by 2028. Source: January 19, 2021, Facts & Factors.

NuLife Market Strategy

  • NuLife will leverage agreements and relationships with a network of over 2,000 Independent Brand Partners (IBPs)/Customers in addition to 1,600+ preferred customers. Since NuLife exclusively markets the MyBody supplement line, distributes GlycoCheck™, and markets additional products in the anti-aging category. IBPs are motivated to be first in the direct sales channel market to offer the patented GlycoCheck™ and patented Endocalyx™ dietary supplements, as well as the line of My Body Rx™ products that are exclusive to NuLife.

NuLife’s compensation plan in the direct selling industry today is focused on recruiting, training, and create the right behaviors that sustain recurring revenue and stability. Another advantage is state-of-the-art industry leading technology, a back office which provides replicated websites for each brand partner, sales, and commission tracking engine. NuLife utilizes an industry leading social sharing app tool which shares compliant marketing videos, fact sheets, and tracks customer engagement for the sharing of products in today’s digital gig economy.

Competitive Advantages

NuLife Sciences

NuLife has an educated and passionate existing team and base of people of over 2,000 independent brand partners who are focused on and understand. microcirculation and its important role in improving anti-aging, health, and longevity. NuLife’s corporate team has over 30 years of combined experience and success in the direct sales space. NuLife’s compensation plan in the direct selling industry today is focused on recruiting, training, and create the right behaviors that sustain recurring revenue and stability. Another advantage is state-of-the-art industry leading technology, a back-office that provides replicated websites for each brand partner, sales, and commission tracking engine. NuLife utilizes an industry leading social sharing app tool which shares compliant marketing videos, fact sheets, and tracks customer engagement for the sharing of products in today’s digital gig economy.

Microvascular Health Solutions

Hans Vink, PhD is a pioneer and a leader in endothelial glycocalyx science and microcirculation. He is the co-founder and chief science officer of MVHS. Dr. Vink has published over 100 peer-reviewed papers and his work has been cited in over 12,000 scholarly articles. MVHS is the exclusive worldwide distributor and manufacture of the GlycoCheck™ system. GlycoCheck™ is the only system in the world with patented clinically validated software to assess, measure, and analyze endothelial glycocalyx function. Endocalyx™ is the only internationally patented nutraceutical focused on the restoration, regeneration, and protection of the endothelial glycocalyx. Endocalyx™ has been shown in studies to improve and repair glycocalyx and microvascular function in aging, cardiovascular, diabetes, kidney disease, inflammation, hypertension, wound healing, and sepsis. To date, thousands of people worldwide have taken Endocalyx™ with no reported negative side effects or conflicts with other medications.

GlycoCheck™

The GlycoCheck™ system is the only medical device worldwide to assess the status of the endothelial glycocalyx and monitor the health of the microvascular system. It has been in use globally since 2011 in over 120 medical centers and academic research hospitals. The GlycoCheck™ method to assess the status of the glycocalyx is patented internationally. More than 70 peer-reviewed clinical research studies have been published using GlycoCheck™. Recent studies have linked traditional risk markers to the MicroVascular Health Score™ as determined by the GlycoCheck™ system such as hypertension, diabetes, aging, smoking, obesity, and gender.

My Body Rx™

Access to the GlycoCheck™ system to test for synergistic effects of supplements on improving the health of the glycocalyx, which in turn supports the entire body including the blood, brain, heart, lungs, kidneys—all organs—muscles, and tissues. In addition to the patented Endocalyx™ formula, My Body Rx™ have proprietary formulas that use the protected method of nano-chelation for absorption and processing all essential minerals.